Benefits
Anxiety and stress reduction
In small placebo-controlled studies in healthy volunteers, a single dose lowered subjective anxiety and heart-rate reactivity during a laboratory stress task, while another stress task showed no effect. A brain-imaging study found reduced amygdala reactivity to threatening faces, consistent with a calming, generally non-sedating profile.
Cognitive flexibility and executive function
In a three-week randomized, double-blind, placebo-controlled crossover trial in 21 healthy adults, 25 mg daily improved measures of cognitive set flexibility and executive function versus placebo on a computerized neurocognitive battery. Participants also reported positive changes in mood and sleep.
Mood enhancement and emotional wellbeing
Participants in the cognition crossover trial reported positive changes in mood, and some volunteers in a three-month tolerability study noted improved coping with stress in their diaries. These mood observations are secondary and come from small studies, so they point to general wellbeing support rather than a measured antidepressant effect.
Calming profile that may support sleep
By easing anxiety without heavy sedation, the extract may support more restful sleep and better next-day alertness. Direct sleep trials are lacking, so this reflects its calming profile and the sleep improvements some trial participants reported, rather than measured changes in sleep architecture.
Mechanism of action
Serotonin reuptake inhibition (SRI)
Mesembrine and mesembrenone inhibit the serotonin transporter (SERT), reducing serotonin reuptake from the synaptic cleft and increasing serotonin availability in brain circuits that govern mood, anxiety, and social behavior. The Sceletium alkaloids bind SERT reversibly, which is associated with the extract's mood and stress effects at the doses used in studies.
PDE4 inhibition and cAMP elevation
Mesembrenone inhibits phosphodiesterase 4 (PDE4), an enzyme that degrades cyclic AMP (cAMP) in neurons. Higher neuronal cAMP activates PKA and CREB signaling, which supports synaptic plasticity and the executive-function and cognitive-flexibility changes seen in the human crossover trial.
5-HT2C receptor modulation
Sceletium alkaloids modulate 5-HT2C serotonin receptors, which help regulate dopamine release in the prefrontal cortex and stress reactivity. This receptor activity is thought to complement serotonin-transporter inhibition in the extract's calming and cognitive effects.
Clinical trials
Randomized, double-blind, placebo-controlled crossover trial of Zembrin (25 mg/day) for three weeks versus placebo in 21 cognitively healthy adults using a computerized neurocognitive battery. (Chiu et al. 2014, Evid Based Complement Alternat Med)
21 healthy adults (mean age about 55); three-week randomized placebo-controlled crossover design.
At 25 mg daily, Zembrin significantly improved cognitive set flexibility and executive function versus placebo on the CNS Vital Signs battery. Participants also reported positive changes in mood and sleep, and the extract was well tolerated.
Two placebo-controlled, double-blind, between-subjects studies of a single 25 mg dose of Zembrin in 20 healthy volunteers, using a multitasking stressor and a simulated public-speaking stressor. (Reay et al. 2020, Hum Psychopharmacol)
20 young healthy volunteers across two between-subjects studies; single-dose design.
The multitasking study showed no treatment effect on mood. In the public-speaking study, subjective anxiety was significantly lower in the Zembrin group before the stressor and there was a significant treatment-by-time effect on heart rate. The authors describe this as first tentative behavioral evidence of an anxiolytic effect.